Capture Pharmaceuticals

Capture Pharmaceuticals was a private biotechnology company formed around technology from the University of North Carolina at Chapel Hill to develop orally bioavailable chelators for radionuclide decorporation and heavy metal removal. Its lead program, C2E2, is an oral DTPA prodrug designed to treat internal contamination from transuranic radioactive elements such as americium and plutonium after nuclear incidents or radiological attacks. The company also explored related chelation applications including gadolinium removal. Publicly available records suggest the original Capture Pharmaceuticals entity is no longer active, while the program and branding later appeared under Captura Biopharma. The business appears to have been focused on emergency preparedness and medical countermeasure markets rather than mainstream chronic therapeutics.